- $9.56bn
- $2.59bn
- $3.24bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.88 | ||
| Price to Tang. Book | 0.88 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 2.95 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -33.05% | ||
| Return on Equity | -28.77% | ||
| Operating Margin | -121.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 803.39 | 18,471 | 19,263 | 6,848 | 3,236 | 2,176.75 | 2,656.85 | 121.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | -29 | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
Directors
- Noubar Afeyan NEC
- Stephen Hoge PRE
- Stephane Bancel CEO
- David Meline CFO
- Tracey Franklin CHO (41)
- Juan Andres CTO (56)
- Lori Henderson GCN (59)
- Marcello Damiani OTH (51)
- Ray Jordan OTH (67)
- Corinne Le Goff OTH (55)
- Jose Vega OTH
- Tal Zvi Zaks OTH (56)
- Shannon Klinger SEC (50)
- Stephen Berenson IND (60)
- Sandra Horning IND (72)
- Robert Langer IND
- Elizabeth Nabel IND (69)
- Francois Nader IND (64)
- Paul Sagan IND (62)
- Elizabeth Tallett IND (72)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 22nd, 2016
- Public Since
- December 7th, 2018
- No. of Shareholders
- 63
- No. of Employees
- 5,800
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Select Market- Shares in Issue
- 386,622,604
- Address
- 325 BINNEY STREET, Cambridge, 02142
- Web
- https://www.modernatx.com/
- Phone
- +1 6177146500
- Auditors
- Ernst & Young LLP
Latest News for MRNA
Upcoming Events for MRNA
Moderna Inc Annual Shareholders Meeting
Q1 2025 Moderna Inc Earnings Call
Q1 2025 Moderna Inc Earnings Release
Moderna Inc Annual Shareholders Meeting
Q2 2025 Moderna Inc Earnings Release
Similar to MRNA
2Seventy Bio
NASDAQ Global Select Market
4D Molecular Therapeutics
NASDAQ Global Select Market
Aardvark Therapeutics
NASDAQ Global Select Market
AbCellera Biologics
NASDAQ Global Select Market
AbSci
NASDAQ Global Select Market
FAQ
As of Today at 22:05 UTC, shares in Moderna are trading at $24.72. This share price information is delayed by 15 minutes.
Shares in Moderna last closed at $24.72 and the price had moved by -76.11% over the past 365 days. In terms of relative price strength the Moderna share price has underperformed the S&P500 Index by -77.53% over the past year.
The overall consensus recommendation for Moderna is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreModerna does not currently pay a dividend.
Moderna does not currently pay a dividend.
Moderna does not currently pay a dividend.
To buy shares in Moderna you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $24.72, shares in Moderna had a market capitalisation of $9.56bn.
Here are the trading details for Moderna:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: MRNA
Based on an overall assessment of its quality, value and momentum Moderna is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Moderna is $50.96. That is 106.19% above the last closing price of $24.72.
Analysts covering Moderna currently have a consensus Earnings Per Share (EPS) forecast of -$10.16 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Moderna. Over the past six months, its share price has underperformed the S&P500 Index by -49.38%.
As of the last closing price of $24.72, shares in Moderna were trading -56.2% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Moderna PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $24.72.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Moderna's management team is headed by:
- Noubar Afeyan - NEC
- Stephen Hoge - PRE
- Stephane Bancel - CEO
- David Meline - CFO
- Tracey Franklin - CHO
- Juan Andres - CTO
- Lori Henderson - GCN
- Marcello Damiani - OTH
- Ray Jordan - OTH
- Corinne Le Goff - OTH
- Jose Vega - OTH
- Tal Zvi Zaks - OTH
- Shannon Klinger - SEC
- Stephen Berenson - IND
- Sandra Horning - IND
- Robert Langer - IND
- Elizabeth Nabel - IND
- Francois Nader - IND
- Paul Sagan - IND
- Elizabeth Tallett - IND